Skip to main content
. 2020 Jan 10;38(2):202–211. doi: 10.1016/j.vaccine.2019.10.030

Table 1.

Characteristics of participants in a cross-sectional carriage and contact survey in Fiji, 2015.

Characteristics iTaukei
Fijian of Indian Descent
Pb
(n = 1212a) (n = 802a)
Male, n (%) 511 (42.2) 319 (39.8) 0.29



Participant group, n (%) 0.95
Young infants 303 (25.0) 193 (24.1)
Toddlers 301 (24.8) 197 (24.6)
Young children 303 (25.0) 207 (25.8)
Caregivers 305 (25.2) 205 (25.5)



Residence, n (%) 0.29
Urban 641 (52.9) 405 (50.5)
Rural 571 (47.1) 397 (49.5)



Symptoms of URTI, n (%) 393 (32.4) 163 (20.3) <0.01



Antibiotics in past fortnight, n (%) 43 (3.6) 18 (2.2) 0.09



Exposure to household cigarette smoke, n (%) 658 (54.3) 429 (53.5) 0.73



Povertyc, n (%) 631 (52.1) 426 (53.1) 0.64



Household size, mean (95% CI)
All ages 8.1 (7.9, 8.3) 5.7 (5.6, 5.8) <0.01
Aged <18 years 3.8 (3.7, 4.0) 2.3 (2.2, 2.4) <0.01
Aged <5 years 2.1 (2.1, 2.2) 1.4 (1.4, 1.5) <0.01
PCV10 vaccinatedd, n %) 375 (30.9) 238 (29.7) 0.55



Pneumococcal carriage, n/N; % (95% CI)
Overalle 538/1195; 45.0 (42.2, 47.9) 108/797; 13.5 (11.2, 16.1) <0.01
PCV10 serotypesf 85/1182; 9.0 (7.5, 10.8) 29/796; 3.6 (2.4, 5.2) <0.01
Non-PCV10 serotypesg 476/1182; 38.3 (35.5, 41.2) 80/796; 10.0 (8.5, 12.3) <0.01
Pneumococcal densityh n; median (IQR) 538; 4.9 (4.0, 5.7) 108; 4.7 (3.9, 5.5) 0.16

URTI: upper respiratory tract infection.

a

Unless otherwise indicated.

b

χ2 test and t-tests compared categorical and continuous variables, respectively.

c

Family income <FJ$175/wk. [23].

d

Received at least two doses of PCV10.

e

Any pneumococci, including non-encapsulated pneumococci.

f

Pneumococci included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F).

g

Pneumococcal serotypes not included in PCV10, nor serotype 6A, including non-encapsulated pneumococci.

h

Includes only participants who were pneumococcal carriers.